Basic Information
| LncRNA/CircRNA Name | HOXA-AS2 |
| Synonyms | HOXA-AS2, HOXA3as |
| Region | GRCh38_7:27107777-27134302 |
| Ensemble | ENSG00000253552 |
| Refseq | NR_122069 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, RNAi, Western blot, RIP, ChIP, Flow cytometry assay, Cell proliferation assay etc. |
| Sample | CRC tissues, cell lines (HCT116, DLD1, SW480, SW620, HT-29 and LOVO) |
| Expression Pattern | up-regulated |
| Function Description | HOXA-AS2 is significantly upregulated in CRC tissue. HOXA-AS2 knockdown significantly suppressed proliferation by blocking the G1/S transition and caused apoptosis of CRC cells in vitro and in vivo. The mechanistic investigations showed that HOXA-AS2 could interact with EZH2, LSD1 and recruit them to p21 (CDKN1A), KLF2 promoter regions to repress their transcription. Furthermore, the rescue experiments demonstrated that HOXA-AS2 oncogenic function is partly through regulating p21. |
| Pubmed ID | 28112720 |
| Year | 2017 |
| Title | Long noncoding RNA HOXA-AS2 represses P21 and KLF2 expression transcription by binding with EZH2, LSD1 in colorectal cancer. |
External Links
| Links for HOXA-AS2 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |